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 Opioid use disorder (OUD) is understood to be a chronic relapsing disorder that, even 
though successful recovery is possible with appropriate treatment, engages and effects the 
function in brain reward pathways in the central nervous system (CNS), potentially leading to 
higher rates of relapse (Blanco & Volkow, 2020). Continual consumption of opioids can 
potentially lead to the development of dependence and/or tolerance of the drug. Patients that 
develop a dependence on the drug often have a difficult time weaning off it due to the 
discomfort of withdrawal. The current study assessed if an enriched environment (EE) 
mediated the withdrawal symptoms within an opioid dependent rat. Previous research has 
demonstrated the beneficial effects EE has on withdrawal and drug seeking behavior (Glaj, 
Barrera, & Ranaldi, 2019). If EE does mediate withdrawals, this can provide better treatment 
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 The growing misuse of opioids is considered the most profound public health issue 
our nation has faced (Vadivelu, Kai, Kodumudi, Sramcik, & Kaye, 2018). In 2017, more than 
70,000 Americans died from a drug overdose, the majority of them originating from opioid 
or opioid-based prescription drugs (Galaj, Barrera, & Ranaldi, 2019). Opioids, such as 
oxycodone (Oxycontin) are commonly prescribed for pain management (Zanni, DeSalle, 
Deutsch, Barr, & Eisch, 2020) but the increasing easy access to these medications is a 
contributing factor for higher rates of addiction, tolerance, and dependence around the world 
(Weiss & Rao, 2016).  
 Opioids have been and are prescribed for the treatment of severe acute, surgical, and 
cancer pain (Furlan, Sandoval, Mailis-Gagnon, & Tunks, 2006). Distinction should be made 
when prescribing opioids to treat cancer pain and acute, chronic non-cancer pain (CNCP) as 
their significance and management vary (Shipton, Shipton, & Shipton, 2018). For instance, 
prescribing opioids for the treatment of CNCP includes the possibility of turning into a 
destructive phenomenon leading to an overwhelming impact psychologically, socially, 
physically, and economically (Shipton et al., 2018). Over prescription of opioids to CNCP 
patients may also be a contributing factor to widespread misuse of opioids and illicit opioid 
overdose-related deaths (Shipton et al., 2018).  
 Conceptualizing opioid use disorder and the many contributing factors associated 
with its development and maintenance may help clinicians better comprehend and provide 
the best course of treatment and how to achieve a reduction in relapse rates and maintain  





Dependence and Tolerance 
 Some of the factors that help define opioid addiction include the compulsion to seek 
out and take opioids and a lack of control in limiting opioid intake (Strang, Volkow, 
Degenhardt, Hickman, Johnson, Koob, Marshall, Tyndall, & Walsh, 2020). The development 
of tolerance and physical dependence are effects produced from the consumption of opioids 
in cancer and noncancer pain populations, but they should not be confused with addiction 
(Jage, 2004). Tolerance is developed when there is desensitization of the opioid receptors, 
often leading to consuming a higher dosage of the drug to get the same effect (Wang, Chen, 
Lee, & Cheng, 2019). Dependence arises from the repeated use of opioids combined with 
craving the drug in order to prevent and/or mediate withdrawal symptoms (Blanco & 
Volkow, 2019; Wang, 2018). Risk of relapse is heightened due to the increase in tolerance of 
opioid receptors and the neurobiological changes that take place within the central nervous 
system (CNS) caused by repeated misuse and abuse of opioids (Wang et al., 2019). 
 From a clinical standpoint, opioid withdrawal is a major contributing factor in the 
development of opioid dependence and addictive behaviors (Kosten & George, 2002). When 
an individual uses opiates (oxycodone, morphine, hydrocodone, etc.), the compound then 
binds to mu opioid receptors (MORs) triggering the biochemical brain processes relating to 
reward and pleasurable feelings (euphoria) (Kosten & George, 2002). This activates the 
mesolimbic system in the brain that then generates signals to the ventral tegmental area 
(VTA) to release the neurotransmitter (NT) dopamine (DA) into the nucleus accumbens 
(NAc) (Kosten & George, 2002). The release of DA is also linked to feelings of pleasure 
(Kosten & George, 2002). With this, the brain then creates memories that can be associated 





seeking related behaviors (Kosten & George, 2002). Understanding all the factors, systems, 
and brain regions that play into the development of tolerance, dependence, and ultimately 
addiction is crucial for effective interventions to prevent and/or stop cognitive deterioration 
(Wang et al., 2019). 
Withdrawal 
As opioid use disorder (OUD) prevalence continues to rise, opioid withdrawal will 
continue to rise as well. Opioid withdrawal is a condition resulting from the reduction or 
cessation of opioid use in an individual that developed a dependence following chronic usage 
of the drug (Stark, 2020). Current medications used for the treatment of OUDs include 
methadone (a full mu-opioid receptor agonist that reduces illicit opioid use gradually), 
buprenorphine (partial mu-opioid receptor agonist), and naltrexone and naloxone (mu-opioid 
antagonists used to reverse overdoses) (Blanco & Volkow, 2019; Wang, 2018). There are 
three major opioid receptors found throughout the (CNS): mu, kappa, and delta (Pergolizzi, 
Raffa, & Rosenblatt, 2020). They are part of the body’s endogenous opioid system, which is 
responsible for the regulation of pain, reward, and addictive behaviors (Contet, Kieffer, & 
Befort, 2004). When endogenous (endorphins, enkephalins, and dynorphins) and exogenous 
opioids (opioids that are introduced from outside the body) bind to opioid receptors, mu 
specifically, this interaction triggers a cascade of chemical signals in the CNS such as 
reducing the excitability of neurons leading to pain relief and euphoria (Contet et al., 2004). 
This interaction additionally increases the production of the neurotransmitter DA, which is 
responsible for reward-seeking behavior, attention, and mood (Contet et al., 2004). 
According to the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) 





tears) or rhinorrhea (excess nasal drainage), nausea/vomiting, diarrhea, pupillary dilation and 
photophobia (light sensitivity), insomnia, yawning, and autonomic hyperactivity 
(hypertension, hyperthermia, tachycardia, sweating, hyperreflexia, tachypnea) (Shah & 
Huecker, 2021). In non-human animals, spontaneous and precipitated withdrawal behaviors 
include head movement (lateral and rotary movement of the head), high walking (elevated 
torso or spine curved upwards), jumping, ptosis (one or both eyelids closed or semi closed), 
wet dog shakes (rapid shaking of whole body), burrowing, diarrhea, yawning, stretching, and 
teeth chattering (constant chattering of teeth/movement of the jaw) (Zanni et al., 2020). 
Severity of withdrawal is dependent upon dosage, duration, and continuity of opiate 
usage (Shah& Huecker, 2021). It can also be precipitated by administration of opioid 
agonists (buprenorphine, naloxone, and naltrexone) (Shah & Huecker, 2021). Opioid 
withdrawal causes varying levels or discomfort and distress; therefore, it is important to 
recognize these withdrawal symptoms in order to facilitate symptom relief for patients and 
establish proper treatment methods for those individuals seeking help (Shah & Huecker, 
2021). 
Environmental Enrichment 
 Although pharmacotherapies such as buprenorphine, methadone, and naltrexone are 
often some of the first steps taken against opioid use disorders, there have been other 
implementations like behavioral interventions (e.g., cue-exposure therapy and contingency 
management therapy), but they have also demonstrated to have short lasting effectiveness 
(Galaj, 2019). Environmental enrichment (EE) is the process of exposing laboratory animals 
to a social and/or physical type of stimulation (Simpson & Kelly, 2011). Physical enrichment 





gnawing toys and other appropriately sized toys not typically incorporated into standard 
environments (SE) of living. Social enrichment or social interaction is simply housing more 
animals together, if and when possible.  
 Previous research has demonstrated that rats housed in larger cages filled with objects 
used for physical enrichment (novel objects or toys and running wheels), had larger cerebral 
cortices and greater amounts of cortical acetylcholinesterase (AChE) when compared to rats 
in isolation and/or standard environments of living (Galaj et al., 2019). In addition, EE has 
demonstrated the modification of neurochemical parameters of brain-derived neurotrophic 
factor (BDNF, a protein that helps the regulation of synaptic plasticity) and cholinergic and 
glutamatergic systems, all which are important for learning and memory (Galaj et al., 2019). 
In this same study, EE induced neural adaptations in the nucleus accumbens and dorsal 
striatum, the regions responsible for motivation and habit formation, respectively (Galaj et 
al., 2019). Another study conducted by Imperio and colleagues (2018) found that EE 
decreased the willingness to work for heroin and reduced the addiction-like behavior in 
heroin experienced rats.  
 Researchers suggest that since EE is a behavioral intervention already applied to 
preclinical and clinical populations, it provides the understanding for significant changes 
regarding neuronal and behavioral functions (Galaj et al., 2019). Overall, previous studies 
indicate that the implementation of EE may decrease drug-seeking behavior and diminish 
cue-induced relapse-like behaviors (Imperio, McFalls, Hadad, Blanco-Berdugo, Masser, 
Colechio, Coffey, Bixler, Stanford, Vrana, Grigson, & Freeman, 2018).  
Given the benefits noted and the lack of effective treatments for the prevention of 





and non-human animal studies and can be a contribution to the development of better therapy 
methods that will help attenuate high relapse rates, maintain long-term recovery, and may 
help individuals struggling with substance use disorders regain control over their impulsivity 
(Galaj et al., 2019). 
Treatment 
 The opioid epidemic has and will remain a crucial issue that will not resolve easily. 
Opioid use disorders and opioid addiction is a chronic mental illness that may cause an 
opioid dependent individual to experience multiple relapses and remissions throughout their 
lifetime (Wang, 2019). This may be due to changes in the regions of the brain involved in 
reward processing and reward-related learning, incentive motivation, and habit forming and 
compulsivity, all behaviors that relate to drug addiction development (Galaj et al., 2019).  
Previously mentioned, there are currently three medications approved for treating 
OUDs: buprenorphine, methadone, and naltrexone (extended release) (Volkow & Collins, 
2017). These medications have proven to be effective in improving mortality rates, treatment 
retention, and remission, but many individuals remain untreated (Wakeman, Larochelle, 
Ameli, Chaisson, McPheeters, Crown, Azocar, & Sanghavi, 2020). Even so, it is estimated 
that 5.3 to 15.3% of individuals maintain abstinence from drugs for more than a year after the 
cessation of pharmacotherapy, leading to staggering rates of relapse (Galaj et al., 2019). 
Previous studies indicate that these medications paired with psychosocial support are 
becoming the standard care for reducing illicit opioid use, overdoses, relapse rate, and can 
improve social function (Volkow & Collins, 2017) but there is still an urgent need for more 





As literature continues to expand, intervention strategies involving EE have proven to 
be highly effective in the treatment of psychological and neurological disorders like addiction 
(Galaj et al., 2019). In the human population, there have been concerns about the translation 
of therapeutic benefits of EE to those individuals struggling with substance use disorders 
(SUDs). The suggestion of incorporating enhanced cognitive stimulation, physical activity, 
and social interaction into the everyday lives of drug-addicted individuals can hinder drug-
related behaviors (Galaj et al., 2019). In addition, the strengthening of social support from 
non-drug using family members, friends, colleagues, program groups, sponsors, and peers 
play a crucial role in the recovery process of these individuals and has shown longer 
participation of treatment programs and prolonged abstinence from drug usage (Galaj et al., 
2019).  
Hypothesis/Purpose 
 The aim of this study was to investigate whether exposure to an enriched environment 
during the induction of opioid dependence mediates withdrawal symptoms in opioid-
dependent female rats. We hypothesized that the oxycodone enriched environment 
(OXY/EE) group would show fewer signs of withdrawal when compared to the oxycodone 
standard environment (OXY/SE) group. 
8 
METHODS 
Animals and Housing 
Thirty-two female Sprague-Dawley rats (aged one month) were ordered from 
ENVIGO and transported to the Jackson Street Psychology Laboratory. Upon arrival, the rats 
were housed two to a cage in a semi-self-contained housing system (Optirat). They had ad 
libitum access to food and water and the vivarium maintained a 12-h light/dark cycle for the 
entirety of the study. Due to some unforeseen circumstances, the rats acclimated to their 
environment for approximately one month after arrival. EE 
Standard and Enriched Environments 
All 32 rats were divided, at random, into four groups (n=8): saline standard 
environment (Sal/SE), saline enriched environment (Sal/EE), oxycodone standard 
environment (Oxy/SE), and oxycodone enriched environment (Oxy/EE). Standard 
environment of living consisted of generalized cages measuring 14 in. L x 19.1 in. W x 8.6 
in. H. Enriched environment of living consisted of the same cage with the inclusion of a 
chewing toy and longer handling/interaction time. In addition, EE rats were placed in 
environmental cages measuring 18 in. L x 14 in. W x 23 ¼ in. H for an hour everyday. These 
cages also included chewing toys and running wheels.  
Drug Administration 
 After the animals were randomly assigned to their experimental/control group and 
the first week of habituation was completed, they underwent a two-week (14 consecutive 





order to build up their dependency on the drug. Dosages administered are consistent with 
extant literature (10.0 mg/kg) (Miladi-Gorji, Rashidy-Pour, & Fathollahi, 2011).  
Procedure 
 Week one of the current study was considered a habituation week, where all 32 of the 
subjects were handled for 5 minutes each for 7 consecutive days. Following this, all animals 
in the environmental enrichment group were placed in the designated EE cages for an hour 
after handling. There were two cages, Sal/EE was in one (n=8) and Oxy/EE was in the other 
(n=8). Upon the completion of habituation, each rat received subcutaneous injections of 
either oxycodone or saline (dependent on the group they were randomly assigned to) for the 
following 14 consecutive days. Rats in the standard environment of living were returned to 
their home cages after injections. Rats in the enriched environment of living were placed in 
the designated EE cages for an hour and then returned to their home cages.  
 On day twenty-one (after 14 consecutive days of drug/no-drug administration), the 
rats were administered 1.0 mg/kg of naloxone (Zanni et al., 2020) and withdrawal behaviors 
were then assessed. Each group was administered the 1.0 mg/kg of naloxone at a time and 
withdrawal behaviors were then recorded for 30 minutes. 
 Observers blind to the study were asked to analyze the 30-minute videos taken on 
withdrawal day. Interrater reliability was then calculated from the scores collected from the 
raters. Withdrawal symptoms were rated according to adaptations from previous studies that 
used the Gellert-Holtzman withdrawal rating scale (Harvey-Lewis, Perdrizet, & Franklin, 
2012; Miladi-Gorji et al., 2011; Zanni et al., 2020): teeth chattering, diarrhea (0 = absent; 1 = 





(Zanni et al., 2020), and wet dog shakes (1-2 shakes = 2; 3-4 = 3; 4 or more = 4) (Miladi-
Gorji et al., 2011). After all groups went through withdrawal, they were returned to their 






 Interrater reliability was calculated with Cronbach’s Alpha, a measurement used for 
internal consistency (reliability), from the summated scores collected from each rater after 
observing opioid withdrawal (see Table 1).  
 
Cronbach’s Alpha   
0.345 
Table 1: Interrater reliability for all withdrawal behaviors. 
 
 The scale had a low level of internal consistency, as determined by a Cronbach’s 
alpha of 0.345. These results indicate a low level of internal consistency for the summation 
of withdrawal behaviors observed between raters.  
Furthermore, since two of the four withdrawal symptoms (diarrhea and ptosis) were 
scored based on a rating scale, all variables were converted into Z-scores to combine all 
withdrawal behaviors to be able to compute for an overall withdrawal score. To be able to 
test the hypothesis that environmental enrichment mediates withdrawal symptoms within an 
opioid dependent rat.  
A One-Way ANOVA was conducted to determine the effect of environmental 
enrichment on the withdrawal symptoms in opioid dependent rats. There were no statistical 
differences between environmental enrichment and the anticipated withdrawal symptoms, 
F(3, 15) = 2.37, p > 0.05 (p = 0.111). Means and standard deviation for all groups can be 







N Mean SD 
SE/Oxy 8 1.65 2.61 
SE/Sal 8 -0.415 2.05 
EE/Oxy 8 -0.080 2.23 
EE/Sal 8 -1.152 1.30 
Table 2: Means and standard deviations of zscores for One-Way ANOVA 
 A Two-Way ANOVA was conducted to compare the two independent variables 
(drug/no drug and environment) to overall withdrawal. Results showed a significant 
difference between saline and oxycodone administration when examining overall withdrawal, 




Environment Mean SD 
Oxy SE 1.65 2.6 
 EE -0.08 2.0 
Saline SE -0.41 2.2 
 EE -1.15 1.3 






 Based on previous research, the current study hypothesized that an enriched 
environment would mediate withdrawal symptoms in an opioid dependent rat. Findings 
showed that enriched environments had no overall effect on withdrawal, but there was a 
difference between saline and oxycodone, suggesting that oxycodone had more of an impact 
on withdrawal when compared to the saline group, which was to be expected. 
 Even though EE has shown to be useful for the reduction of drug seeking behavior, 
modifying neural circuits in regions of the brain relating to compulsive drug seeking, and has 
reduced stress, which plays a role in relapse, prolonged EE intervention in pre-clinical 
settings should be considered for future studies (Galaj et al., 2019). Additionally, drugs of 
abuse such as opiates have profound neurobiological effects both structurally and 
functionally, even after reduction or cessation of drug use (Imperio et al., 2018). Possibility 
of introducing EE after the acquisition of opioid self-administration, heroin specifically, may 
facilitate abstinence for longer periods of time (Galaj et al., 2019). 
Limitations 
 One limitation during the current study was the groups sample size (n = 8). With a 
larger sample size, there may have been the possibility of observing proper withdrawal 
behaviors and greater interpretation of results within the groups (Hackshaw, 2008). 
 Although EE rats were exposed to both physical and social enrichment, their time in 
the designated EE cages was restricted to only an hour per day. Significant differences may 
have been seen if rats were allowed to be permanently placed or housed in an enriched 





of standard environment of living might have provided a greater understanding on the 
severity of withdrawal in opioid dependent rats (Galaj et al., 2019). 
Implications and Concluding Remarks 
 Despite the encouraging results of pharmacological treatment approaches to 
combat substance use disorders like OUDs, effective long-term treatments are still limited 
(Imperio et al., 2018).  The present study examined the effect of exposure to EE following 
the development of dependence of opioids within rat models. Although results showed no 
supporting evidence for the hypothesis made, previous research has demonstrated that EE 
can still be useful in the treatment of SUDs in rodent models (Yazdanfar, Farnam, Sadigh-
Eteghad, & Mahmoudi, 2021).  
 The increasing use and misuse of opioids will continue to cause public health 
challenges within our nation (Zanni et al., 2018) but the expansion of new approaches for 
treatment involving the strengthening of social support may positively impact those 
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